The drug regorafenib significantly prolongs survival in people with liver cancer who do not respond to other treatments, according to an international study led by Hospital Clínic.

The study, which marks the first breakthrough against this type of tumor since 2007, is the most outstanding result of the World Congress of Gastrointestinal Cancer that is celebrated this week in Barcelona.

Regorafenib is already approved in Europe for the treatment of colorectal cancer and a rare cancer called GIST, so "its approval for liver cancer should be rapid," says Jordi Bruix, director of Barcelona Clinic Liver Cancer, who Has led the study. Looking to the future, "the new results open the way to more advances, for example combining drugs; What is expected is that we do not have to wait another decade for the next qualitative leap" More information.